162 related articles for article (PubMed ID: 21965474)
1. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths.
Neppl-Huber C; Zappa M; Coebergh JW; Rapiti E; Rachtan J; Holleczek B; Rosso S; Aareleid T; Brenner H; Gondos A;
Ann Oncol; 2012 May; 23(5):1325-1334. PubMed ID: 21965474
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.
Wever EM; Draisma G; Heijnsdijk EA; Roobol MJ; Boer R; Otto SJ; de Koning HJ
J Natl Cancer Inst; 2010 Mar; 102(5):352-5. PubMed ID: 20142584
[TBL] [Abstract][Full Text] [Related]
3. Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.
McLaughlin PW; Cousins MM; Tsodikov A; Soni PD; Crook JM
Sci Rep; 2024 Mar; 14(1):5810. PubMed ID: 38461151
[TBL] [Abstract][Full Text] [Related]
4. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.
Collin SM; Martin RM; Metcalfe C; Gunnell D; Albertsen PC; Neal D; Hamdy F; Stephens P; Lane JA; Moore R; Donovan J
Lancet Oncol; 2008 May; 9(5):445-52. PubMed ID: 18424233
[TBL] [Abstract][Full Text] [Related]
5. Optimal prostate-specific antigen screening interval for prostate cancer.
Kobayashi D; Takahashi O; Fukui T; Glasziou PP
Ann Oncol; 2012 May; 23(5):1250-1253. PubMed ID: 21948815
[TBL] [Abstract][Full Text] [Related]
6. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
7. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
[TBL] [Abstract][Full Text] [Related]
8. Trends in prostate cancer mortality among black men and white men in the United States.
Chu KC; Tarone RE; Freeman HP
Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening (United States).
Waterbor JW; Bueschen AJ
Cancer Causes Control; 1995 May; 6(3):267-74. PubMed ID: 7542033
[TBL] [Abstract][Full Text] [Related]
13. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
Smart CR
Cancer; 1997 Nov; 80(9):1835-44. PubMed ID: 9351557
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
Boyle P
Ann Oncol; 1998 Dec; 9(12):1263-4. PubMed ID: 9932152
[No Abstract] [Full Text] [Related]
15. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics.
Ondrusova M; Ondrus D; Karabinos J; Muzik J; Kliment J; Gulis G
Tumori; 2011; 97(2):149-55. PubMed ID: 21617707
[TBL] [Abstract][Full Text] [Related]
16. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
17. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality.
Smith DP; Banks E; Clements MS; Gardiner RA; Armstrong BK
Med J Aust; 2009 Aug; 191(4):199-200. PubMed ID: 19705979
[TBL] [Abstract][Full Text] [Related]
19. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.
Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS
J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Welch HG; Albertsen PC
J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
